Pharma companies set for strong performance in March 2025 quarter amid earning (...)
Sun Pharma is expected to post a 9% year-on-year revenue growth, supported by its US specialty portfolio and steady growth in chronic therapies in India.
Site référencé: The Economic Times
The Economic Times
Varun Beverages Q4 results : PAT rises 33% YoY, revenue surges 29%
30/04/2025
The golden illusion : Know the risks behind gold’s safe haven image
30/04/2025
HAL, GRSE and other defence stocks fall up to 5% on profit booking amid India-Pakistan tensions
30/04/2025
IndusInd Bank remains fundamentally strong despite top management exit : Ashvin Parekh
30/04/2025
Trump's tariffs loom over American economy as shipments from China fall
30/04/2025
New York bans smartphones in schools, joining national movement
30/04/2025
